Complications of liver cirrhosis: Oesophageal varices, ascites and hepato-cellular carcinoma;Les complications de la cirrhose hépatique: Varices œsophagiennes, ascite et carcinome hépato-cellulaire

Revue Medicale Suisse

Volumn 1, Issue 3, 2005, Pages 249-255

  Troillet, François Xavier ^a   Halkic, Nermin ^a   Froehlich, Florian ^a,b   Moradpour, Darius ^a   Gonvers, Jean Jacques ^a   Denys, Alban ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ASCITES; BLEEDING; ENDOSCOPY; ESOPHAGUS VARICES; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; RISK FACTOR; SURGICAL TECHNIQUE; SURVIVAL RATE; LIGATION; LIVER TUMOR;

ADRENERGIC BETA-ANTAGONISTS; ASCITES; CARCINOMA, HEPATOCELLULAR; ENDOSCOPY; ESOPHAGEAL AND GASTRIC VARICES; HUMANS; LIGATION; LIVER CIRRHOSIS; LIVER NEOPLASMS;

EID: 15044364919     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Sorbi D, Gostout CJ, Peura D, et al. An assessment of the management of acute bleeding varices: A multicenter prospective member-based study. Am J Gastroenterol 2003; 98: 2424-34.
2. Wu JCY, Chan FKL. Esophageal bleeding disorders. Curr Opin Gastroenterol 2004; 20: 386-90.
3. Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: A Cochrane metaanalysis. Gastroenterology 2003; 124: 1277-91.
4. Ioannou GN, Doust J, Rockey DC. Systematic review: Terlipressin in acute oesophageal variceal hemorrhage. Aliment Pharmacol Ther 2003; 17: 53-64.
5. Banares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A Meta-analysis. Hepatology 2002; 35: 609-15.
6. Yol S, Belviranli M, Toprak S, et al. Endoscopic clipping versus band ligation in the management of bleeding esophageal varices. Surg Endosc 2003; 17: 38-42.
7. Naga MI, Okasha HH, Foda AR, et al. Detachable endoloop vs elastic band ligation for bleeding esophageal varices. Gastrointest Endosc 2004; 59: 804-9.
8. Vangeli M, Patch D, Terreni N, et al. Bleeding ectopic varices - treatment with transjugular intrahepatic portosystemic shunt (TIPS) and embolisation. J Hepatol 2004; 41: 560-6.
9. Lo GH, Chen WC, Chen MH, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal rebleeding. Gastroenterology 2002; 123: 728-34.
10. Patch D, Sabin CA, Goulis J, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123: 1013-9.
11. Lopes CV, Pereira-Lima JC, Pereira-Lima LF, et al. The efficacy of endoscopic ligation for the prevention of variceal rebleeding in cirrhotic patients according to the hepatocellular function. Hepato-Gastroenterol 2004; 51: 195-200.
12. Singh P, Pooran N, Indaram A, Bank S. Combined ligation and sclerotherapy versus ligation alone for secondary prophylaxis of esophageal variceal bleeding: A meta-analysis. Am J Gastroenterol 2002; 97: 623-9.
13. Evrard S, Dumonceau JM, Delhaye M, et al. Endoscopic histoacryl obliteration vs proporanolol in the prevention of esophagogastric variceal rebleeding: A randomized trial. Endoscopy 2203; 35: 729-35.
14. Boyer TD. Transjugular intrahepatic portosystemic shunt: Current status. Gastroenterology 2003; 124: 1700-10.
15. Giannini E, Botta F, Borro P, et al. Platelet count/spleen diameter ratio: Proposal and validation of a non-invasive parameter to predict the presence of oesophageal varices in patienst with liver cirrhosis. Gut 2003; 52: 1200-5.
16. Thomopoulos KC, Labropoulou K, Mimidis KP, et al. Non-invasive predictors of the presence of large oesophageal varices in patients with cirrhosis. Dig Liver Dis 2003; 35: 473-8.
17. Garcia-Pagan JC, Morillas R, Banares R, et al. Propranolol plus placebo versus proporanolol plus isosorbide-5-monotritate in the prevention of a first variceal bleed: A double-blind RCT. Hepatology 2003; 37: 1260-6.
18. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices. Gastroenterology 2004; 127: 476-84.
19. Lo GH, Chen WC, Chen MH, et al. Endoscopic ligation versus nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc 2004; 59: 333-8.
20. Schepke M, Kleber G, Nürnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004; 40: 65-72.
21. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31: 468-75.
22. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 264-72.
23. Shear L, Ching S, Gabuzda GJ. Compartmentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970; 282: 1391-6.
24. Ginès P, Arroyo V, Quintero E, et al. Comparison of pracentesis and diuretics in the treatment of cirrhotics with tense ascites: Results of randomized study. Gastroenterology 1987; 93: 234-41.
25. Salerno F, Badalamenti S, Incerti P, et al. Repeated paracentesis and i.V. albumin infusion to treat «tense» ascites in cirrhotic patients: A safe alternative therapy. J Hepatol 1987; 5: 102-8.
26. Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995; 22: 753-8.
27. Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
28. Ginès P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325: 829-35.
29. Ochs A, Rossle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332: 1192-7.
30. Shiffman ML, Jefferts L, Hoofnagle JH, Tralka TS. The role of transjugular intrahepatic portosystemic shunt for treatment of portal hypertension and its complications: A conference sponsored by the National Digestive Deseases Advisory Board. Hepatology 1995; 22: 1591-7.
31. Ginès P, Uriz J, Calahorra B, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123: 1839-47.
32. Sanyal AJ, Genning C, Reddy KR, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124: 634-41.
33. Ginès A, Escorsell A, Ginès P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
34. Moreau R, Durand F, Poynard T, et al. Terlipressin in patients with cirrhosis and type I hepatorenal syndrome: A retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
35. Ortega R, Ginès P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. Hepatology 2002; 36: 941-8.
36. Guevara M, Ginès P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998; 28: 16-22.
37. Brensing KA, Textor J, Perz J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II study. Gut 2000; 47: 288-95.
38. Mitzner SR, Stang J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective randomized controlled trial. Liver Transpl 2000; 6: 277-86.
39. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
40. Fattovich G, Giuscina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C:A retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
41. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-30.
42. Bruix J, Llovet JM. HCC surveillance: Who is the target population? Hepatology 2003; 37: 507-9.
43. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.
44. Aril S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
45. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127(Suppl. 1): S159-66.
46. Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001; 33: 1124-9.
47. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
48. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002; 8: 873-83.
49. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation. Hepatology 1999; 30: 1434-40.
50. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
51. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions. Radiology 2000; 214: 761-8.
52. Hoofnagle JH. Hepatocellular carcinoma: Summary and recommandations. Gastroenterology 2004; 127: S319-S23.